Seagen Inc.
CD123 Antibodies and Conjugates Thereof
Last updated:
Abstract:
The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
Status:
Application
Type:
Utility
Filling date:
5 Jan 2021
Issue date:
6 May 2021